• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.
    All News #Library

    Enforcement Report - Week of April 15, 2026

    FDA

    Enforcement Report - Week of February 4, 2026

    FDA

    Enforcement Report - Week of March 26, 2025

    FDA

    Mylan Labs is on Health Canada Inspection List

    HEALTH CANADA

    Enforcement Report - Week of January 22, 2025

    FDA

    FDA Issues Form 483 to Mylan Laboratories Ltd

    FDA

    Viatris Receives FDA Warning Letter

    FDA

    Enforcement Report - Week of December 18, 2024

    FDA

    Enforcement Report - Week of July 24, 2024

    FDA

    Health Canada Issues Recall of Mylan-Nitro Sublingual Spray

    HEALTH CANADA

    Enforcement Report - Week of September 27, 2023

    FDA

    Enforcement Report - Week of June 14, 2023

    FDA

    Enforcement Report - Week of November 16, 2022

    FDA

    Mylan Institutional LLC, a Viatris Company, Issues a Voluntary Recall of One Lot of Octreotide Acetate Injection

    FDA

    Enforcement Report - Week of October 5, 2022

    FDA

    Enforcement Report - Week of August 3, 2022

    FDA

    Mylan Pharmaceuticals Inc., a Viatris Company, Issues Voluntary Nationwide Recall of One Batch of Insulin Glargine

    FDA

    Enforcement Report - Week of May 18, 2022

    FDA

    Enforcement Report - Week of May 11, 2022

    PRESS RELEASE

    Enforcement Report - Week of May 4, 2022

    FDA

    Enforcement Report - Week of April 27, 2022

    FDA

    Enforcement Report - Week of April 13, 2022

    FDA

    Mylan Pharmaceuticals Inc., a Viatris Company, Issues Voluntary Nationwide Recall of One Batch of Insulin Glargine Due to the Potential for a Missing Label in the Batch

    FDA

    Enforcement Report - Week of February 2, 2022

    FDA

    Mylan Pharmaceuticals Inc., a Viatris Company, Conducting Voluntary Recall of One Batch of Semglee®

    FDA

    Enforcement Report - Week of October 6, 2021

    FDA

    Enforcement Report - Week of September 22, 2021

    FDA

    Enforcement Report- Week of June 9, 2021

    FDA

    Enforcement Report - Week of September 9, 2020

    FDA

    Mylan Laboratories Limited – Unit 7 Receives FDA Warning Letter

    FDA

    Enforcement Report - Week of August 12, 2020

    FDA

    Mylan Initiates Voluntary Nationwide Recall of One Lot of Daptomycin for Injection

    FDA

    Enforcement Report - Week of May 27, 2020

    FDA

    Enforcement Report - Week of March 25, 2020

    FDA

    Enforcement Report - Week of January 29, 2020

    FDA

    Mylan Initiates Voluntary Nationwide Recall of Three Lots of Nizatidine Capsules

    FDA

    Mylan Laboratories Limited - Unit 8 Receives FDA Warning Letter

    FDA

    Enforcement Report - Week of November 13, 2019

    FDA

    Enforcement Report - Week of November 6, 2019

    FDA

    Mylan Pharmaceuticals Initiates Voluntary Nationwide Recall of One Lot of Alprazolam Tablets

    FDA

    Enforcement Report - Week of September 18, 2019

    FDA

    Enforcement Report - Week of March 27, 2019

    FDA

    Mylan Institutional Recalls Levoleucovorin Injection

    FDA

    Enforcement Report - Week of February 27, 2019

    FDA

    Enforcement Report - Week of February 13, 2019

    FDA

    Enforcement Report - Week of February 6, 2019

    FDA

    Mylan Pharmaceuticals on Health Canada Inspection List

    HEALTH CANADA

    Enforcement Report - Week of December 19, 2018

    FDA

    FDA warns API manufacturer involved in valsartan recall

    FDA

    Mylan expands its voluntary recall of valsartan-containing products

    FDA

    Mylan Expands Voluntary Nationwide Recall of Valsartan Tablets Due to Trace NDEA

    FDA

    Mylan Valsartan medications voluntarily recalled due to an impurity

    HEALTH CANADA

    Valsartan products under recall - Updated November 27, 2018

    FDA

    FDA updates on angiotensin II receptor blocker (ARB) recalls including valsartan, losartan and irbesartan

    FDA

    Teva recalls Amlodipine/Valsartan Tablets & Amlodipine/Valsartan/Hydrochlorothiazide Tablets

    FDA

    TGA Issues Recall of Mylan Australia`s Dilart and Dilart HCT (valsartan)

    TGA

    Mylan Recalls Valsartan tablets, Amlodipine and Valsartan Tablets, and Valsartan and Hydrochlorothiazide Tablets

    Mylan Pharmaceuticals Receives FDA Warning Letter

    FDA

    Valsartan from Mylan laboratories in India can no longer be used in EU medicines due to NDEA impurity

    EMA

    Enforcement Report - Week of October 24, 2018

    FDA

    Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.